BR112012007183A2 - solvato de um sal de um composto macrocíclico, forma polimórfica, processos para preparar a forma polimórfica e uma composição farmacêutica, composição farmacêutica, sal de um composto macrocíclico, e, métodos para estimular motilidade gastrintestinal, para tratar um distúrbio gastrintestinal e para tratar um indivíduo, e, kit - Google Patents
solvato de um sal de um composto macrocíclico, forma polimórfica, processos para preparar a forma polimórfica e uma composição farmacêutica, composição farmacêutica, sal de um composto macrocíclico, e, métodos para estimular motilidade gastrintestinal, para tratar um distúrbio gastrintestinal e para tratar um indivíduo, e, kitInfo
- Publication number
- BR112012007183A2 BR112012007183A2 BR112012007183A BR112012007183A BR112012007183A2 BR 112012007183 A2 BR112012007183 A2 BR 112012007183A2 BR 112012007183 A BR112012007183 A BR 112012007183A BR 112012007183 A BR112012007183 A BR 112012007183A BR 112012007183 A2 BR112012007183 A2 BR 112012007183A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- salt
- pharmaceutical composition
- disorders
- polymorphic form
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 8
- 150000003839 salts Chemical class 0.000 title abstract 7
- 150000002678 macrocyclic compounds Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 5
- 239000012453 solvate Substances 0.000 title abstract 5
- 208000018522 Gastrointestinal disease Diseases 0.000 title abstract 4
- 208000010643 digestive system disease Diseases 0.000 title abstract 2
- 230000005176 gastrointestinal motility Effects 0.000 title abstract 2
- 208000018685 gastrointestinal system disease Diseases 0.000 title abstract 2
- 230000004936 stimulating effect Effects 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 3
- 206010021518 Impaired gastric emptying Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000001288 gastroparesis Diseases 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 208000017701 Endocrine disease Diseases 0.000 abstract 1
- 102000000393 Ghrelin Receptors Human genes 0.000 abstract 1
- 108010016122 Ghrelin Receptors Proteins 0.000 abstract 1
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 208000026350 Inborn Genetic disease Diseases 0.000 abstract 1
- 206010054048 Postoperative ileus Diseases 0.000 abstract 1
- 206010049416 Short-bowel syndrome Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 208000014797 chronic intestinal pseudoobstruction Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000016361 genetic disease Diseases 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D269/00—Heterocyclic compounds containing rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms according to more than one of groups C07D261/00 - C07D267/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24736209P | 2009-09-30 | 2009-09-30 | |
| PCT/US2010/050661 WO2011041369A1 (en) | 2009-09-30 | 2010-09-29 | Salts, solvates, and pharmaceutical compositions of macrocyclic ghrelin receptor agonists and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012007183A2 true BR112012007183A2 (pt) | 2017-06-20 |
Family
ID=43826618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012007183A BR112012007183A2 (pt) | 2009-09-30 | 2010-09-29 | solvato de um sal de um composto macrocíclico, forma polimórfica, processos para preparar a forma polimórfica e uma composição farmacêutica, composição farmacêutica, sal de um composto macrocíclico, e, métodos para estimular motilidade gastrintestinal, para tratar um distúrbio gastrintestinal e para tratar um indivíduo, e, kit |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20110245159A1 (https=) |
| EP (1) | EP2482813A4 (https=) |
| JP (1) | JP2013506676A (https=) |
| KR (1) | KR20120081166A (https=) |
| CN (1) | CN102781441A (https=) |
| AU (1) | AU2010300689A1 (https=) |
| BR (1) | BR112012007183A2 (https=) |
| CA (1) | CA2775925A1 (https=) |
| EA (1) | EA201270497A1 (https=) |
| IL (1) | IL218938A0 (https=) |
| IN (1) | IN2012DN03297A (https=) |
| MX (1) | MX2012003912A (https=) |
| WO (1) | WO2011041369A1 (https=) |
| ZA (1) | ZA201202307B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090198050A1 (en) * | 2003-06-18 | 2009-08-06 | Tranzyme Pharma Inc. | Macrocyclic Modulators of the Ghrelin Receptor |
| US7491695B2 (en) * | 2003-06-18 | 2009-02-17 | Tranzyme Pharma Inc. | Methods of using macrocyclic modulators of the ghrelin receptor |
| US8921521B2 (en) | 2003-06-18 | 2014-12-30 | Ocera Therapeutics, Inc. | Macrocyclic modulators of the Ghrelin receptor |
| US7476653B2 (en) * | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| DK1633774T3 (da) * | 2003-06-18 | 2010-05-25 | Tranzyme Pharma Inc | Makrocykliske motilinreceptorantagonister |
| US8592377B2 (en) | 2007-03-28 | 2013-11-26 | President And Fellows Of Harvard College | Stitched polypeptides |
| ES2711526T3 (es) | 2010-08-13 | 2019-05-06 | Aileron Therapeutics Inc | Macrociclos peptidomiméticos |
| UY34094A (es) | 2011-05-27 | 2013-01-03 | Novartis Ag | Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| BR112014020103A2 (pt) | 2012-02-15 | 2018-10-09 | Aileron Therapeutics, Inc. | macrociclos peptidomiméticos |
| EP2819688A4 (en) | 2012-02-15 | 2015-10-28 | Aileron Therapeutics Inc | TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES |
| WO2014071241A1 (en) | 2012-11-01 | 2014-05-08 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
| EP3197478A4 (en) | 2014-09-24 | 2018-05-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| CN107106636A (zh) | 2014-11-12 | 2017-08-29 | 利瑞克药品有限公司 | 肠内喂养不耐受的治疗 |
| WO2016154058A1 (en) | 2015-03-20 | 2016-09-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| WO2018106945A1 (en) * | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7491695B2 (en) * | 2003-06-18 | 2009-02-17 | Tranzyme Pharma Inc. | Methods of using macrocyclic modulators of the ghrelin receptor |
| US7476653B2 (en) * | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| AU2005280639A1 (en) * | 2004-02-17 | 2006-03-09 | Billy T. Fowler | Methods, compositions, and apparatuses for forming macrocyclic compounds |
| EP1723159B1 (en) * | 2004-02-27 | 2019-06-12 | Melinta Therapeutics, Inc. | Macrocyclic compounds and methods of making and using the same |
| US8088733B2 (en) * | 2006-07-06 | 2012-01-03 | Tranzyme Pharma Inc. | Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders |
-
2010
- 2010-09-29 IN IN3297DEN2012 patent/IN2012DN03297A/en unknown
- 2010-09-29 JP JP2012532258A patent/JP2013506676A/ja not_active Withdrawn
- 2010-09-29 BR BR112012007183A patent/BR112012007183A2/pt not_active IP Right Cessation
- 2010-09-29 AU AU2010300689A patent/AU2010300689A1/en not_active Abandoned
- 2010-09-29 KR KR1020127010634A patent/KR20120081166A/ko not_active Withdrawn
- 2010-09-29 CA CA2775925A patent/CA2775925A1/en not_active Abandoned
- 2010-09-29 US US12/937,040 patent/US20110245159A1/en not_active Abandoned
- 2010-09-29 CN CN2010800547916A patent/CN102781441A/zh active Pending
- 2010-09-29 MX MX2012003912A patent/MX2012003912A/es not_active Application Discontinuation
- 2010-09-29 EA EA201270497A patent/EA201270497A1/ru unknown
- 2010-09-29 EP EP10821147A patent/EP2482813A4/en not_active Withdrawn
- 2010-09-29 WO PCT/US2010/050661 patent/WO2011041369A1/en not_active Ceased
-
2012
- 2012-03-29 ZA ZA2012/02307A patent/ZA201202307B/en unknown
- 2012-03-29 IL IL218938A patent/IL218938A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011041369A1 (en) | 2011-04-07 |
| EA201270497A1 (ru) | 2012-10-30 |
| KR20120081166A (ko) | 2012-07-18 |
| EP2482813A1 (en) | 2012-08-08 |
| MX2012003912A (es) | 2012-08-17 |
| ZA201202307B (en) | 2012-12-27 |
| JP2013506676A (ja) | 2013-02-28 |
| AU2010300689A1 (en) | 2012-04-19 |
| IL218938A0 (en) | 2012-07-31 |
| US20110245159A1 (en) | 2011-10-06 |
| CA2775925A1 (en) | 2011-04-07 |
| IN2012DN03297A (https=) | 2015-10-23 |
| CN102781441A (zh) | 2012-11-14 |
| EP2482813A4 (en) | 2013-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012007183A2 (pt) | solvato de um sal de um composto macrocíclico, forma polimórfica, processos para preparar a forma polimórfica e uma composição farmacêutica, composição farmacêutica, sal de um composto macrocíclico, e, métodos para estimular motilidade gastrintestinal, para tratar um distúrbio gastrintestinal e para tratar um indivíduo, e, kit | |
| EA201270039A1 (ru) | Новые агонисты gpr 119 | |
| BR112012015714A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença neurodegenerativa, método para reduzir a concentração de p-ser-alfa-sinucleina em tecido cerebral, e, método para o tratamento de um câncer | |
| BR112013006344A2 (pt) | lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas | |
| EA200970090A1 (ru) | Модуляторы метаболизма и лечение связанных с ним расстройств | |
| BR112016028345A2 (pt) | composto, composição farmacêutica, métodos para inibir agregação de tau em um mamífero e para avaliar depósitos de tau em um paciente, e, uso de um composto. | |
| EA200901077A1 (ru) | Макроциклические модуляторы грелинового рецептора и их применение | |
| EA201101524A1 (ru) | Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором | |
| MX2012000704A (es) | Agonistas de gpr119. | |
| EA201490569A1 (ru) | Полиморфная форма гидрохлорида придопидина | |
| CL2007003758A1 (es) | Compuestos derivados de aminopirimidina, inhibidores de plk1; composicion farmaceutica, util para el tratamiento de cancer. | |
| MX2009003958A (es) | Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos y su uso. | |
| UY31072A1 (es) | Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido | |
| SG178986A1 (en) | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use | |
| BR112015007182A2 (pt) | inibidores de gdf-8 | |
| EA201491335A1 (ru) | Бигуанидные композиции и способы лечения метаболических расстройств | |
| BR112012012903A2 (pt) | compostos de espiropiperidina | |
| BR112012025592A2 (pt) | moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos | |
| CL2009000381A1 (es) | Compuestos derivados de tiazol o tiazol-5-carboxamida, inhibidores de la actividad estearoil-coa-desaturasa humana (scd); composicion farmaceutica; y uso para el tratamiento de un trastorno o enfermedad mediada por las enzimas de scd, tal como diabetes, obesidad, enfermedad cardiovascular, lipidos elevados, entre otras. | |
| EA201270755A1 (ru) | Аналоги пиримидинилпиперидинилоксипиридинона в качестве модуляторов рецептора gpr119 | |
| BR112012026147A2 (pt) | espiroderivados azacíclicos como inibidores de hsl | |
| MX2011009493A (es) | Compuestos para el tratamiento de trastornos metabolicos. | |
| BR112012009496A2 (pt) | composição farmacêutica, e, método para tratar diabetes tipo 2 | |
| EA201200046A1 (ru) | Новые соединения, фармацевтическая композиция и связанные с ними способы | |
| MX378555B (es) | Proceso para la preparacion de derivados del acido biliar de las sulfonilureas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |